Neurovalens Showcases Ground-breaking Chronic Insomnia Treatment at Medica 2023


ABHI Association of British HealthTech Industries Ltd.

Neurovalens Showcases Ground-breaking Chronic Insomnia Treatment at Medica 2023

Neurovalens, a global leader in non-invasive neuro-technology, has received medical device clearance from the US Food & Drug Administration (FDA) to treat chronic insomnia with its Modius Sleep device.

Based in Belfast, Neurovalens is a health-tech company that specialises in combining neuroscience and technology to tackle a range of global health challenges.

The company’s medical devices have been designed to deliver non-invasive electrical stimulation to key areas of the brain and nervous system without the need for surgically implanted electrodes.

Modius Sleep is designed to improve insomnia by delivering a small and safe electrical pulse to the head for a period of 30 minutes before bed, during which users can do other activities, such as watching TV or reading.

Dr Jason McKeown, CEO of Neurovalens, said: “Having the Modius Sleep technology as a certified medical device for the treatment of chronic insomnia is a landmark step for the company as we focus on future growth in the US market. Most other products on the market measure symptoms of insomnia, but Modius Sleep is a non-invasive device that actually treats the underlying issue, improving the lives of our patients.”

Visit the Neurovalens stand in the ABHI UK Pavilion, Hall 16, K32 and learn more about the Modius Sleep technology, try on the headset and speak to the Neurovalens team.

Exhibitor Data Sheet